ArticleWorld psychiatry : official journal of the World Psychiatric Association (WPA)2023
20-year trajectories of positive and negative symptoms after the first psychotic episode in patients with schizophrenia spectrum disorder: results from the OPUS study.
Article in World psychiatry : official journal of the World Psychiatric Association (WPA), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Systematic Review and Meta-Analysis of Randomized Clinical Trials of Anti-Inflammatory Agents in Early-Stage Psychotic Disorders.Schizophrenia bulletin · 2026Pooled it
- Digital Therapeutics for People with Schizophrenia Spectrum Disorders: A Systematic Literature Review of Their Effect on Symptoms and Functioning.Schizophrenia bulletin · 2026Pooled it
- Accuracy of machine learning methods in predicting prognosis of patients with psychotic spectrum disorders: a systematic review.BMJ open · 2025Pooled it
- Childhood premorbid adjustment as a marker for 20-year impairments in schizophrenia spectrum disorder: results from the OPUS study.European child & adolescent psychiatry · 2026Trial
- The effects of lurasidone on five symptom domains and individual items in schizophrenia: Post-hoc analysis from Phase 3 study.International clinical psychopharmacology · 2026Trial
- Long-Term Trajectories of Multidimensional Outcomes in Psychosis Following Early Intervention During the Critical Period: The PEPP-Montreal 10+ Study Protocol.Early intervention in psychiatry · 2026Article
- Article
- Trajectories of psychotic symptoms and fronto-parietal resting state functional connectivity MRI following an antipsychotic trial in medication-naïve first-episode psychosis patients.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026Article
- Psychosis Mental Health Campaigns: A Scoping Review of Strategies and Outcomes.Early intervention in psychiatry · 2026Article
- Real-world comprehensive care of people living with schizophrenia: recommendations across different settings and clinical stages.World psychiatry : official journal of the World Psychiatric Association (WPA) · 2026Article
- Individualized cortical gradient and network topology reveal symptom-linked disruptions and neurobiological subtypes in schizophrenia.medRxiv : the preprint server for health sciences · 2026Article
- Rethinking language, cognition and assessment in psychosis: How bilingualism challenges psychiatry and how natural language processing can help.Schizophrenia (Heidelberg, Germany) · 2026Review
- Virtual reality-based cognitive remediation in severe mental illness: Current evidence from a narrative review.Schizophrenia research. Cognition · 2026Review
- Selective magnetic stimulation downregulates the GABAMolecular psychiatry · 2026Article
- Affective Reactivity to a Single Bout of High-Intensity Interval Training in Schizophrenia: A Randomized Controlled Trial.Schizophrenia bulletin open · 2026Article
- Comparison of Neurocognitive Effects of Blonanserin, Olanzapine, Aripiprazole, and Risperidone in Drug-Naïve First-Episode Schizophrenia.Neuropsychiatric disease and treatment · 2026Article
- The RECAPACITA PROJECT: comparative study of the clinical, neuropsychological, and functional profile of people with severe mental disorder and partial and total capacity modification.Social psychiatry and psychiatric epidemiology · 2025Article
- Self-Reported Burden Among Informal Caregivers of Patients Receiving Psychiatric Hospital Treatment: A National Cross-Sectional Study.International journal of mental health nursing · 2025Article
- Restoring Course as a Core Diagnostic Element of Psychotic Disorders.Schizophrenia bulletin · 2025Review
- Impact of Washout Duration to Account for Left Truncation in Register-based Epidemiologic Studies: Estimating the Risk of Mental Disorders.Epidemiology (Cambridge, Mass.) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to identify the 20-year trajectories of positive and negative symptoms after the first psychotic episode in a sample of patients with an ICD-10 diagnosis of schizophrenia spectrum disorder, and to investigate the baseline characteristics and long-term outcomes associated with these trajectories. A total of 373 participants in the OPUS trial were included in the study. Symptoms were assessed at baseline and after 1, 2, 5, 10 and 20 years using the Scales for the Assessment of Positive and Negative Symptoms. We used latent class growth mixture modelling to identify trajectories, and multinominal regression analyses to investigate predictors of membership to identified trajectories. Five trajectories of positive symptoms were identified: early continuous remission (50.9% of the sample), stable improvement (18.0%), intermittent symptoms (10.2%), relapse with moderate symptoms (11.9%), and continuous severe symptoms (9.1%). Substance use disorder (odds ratio, OR: 2.83, 95% CI: 1.09-7.38, p=0.033), longer duration of untreated psychosis (OR: 1.02, 95% CI: 1.00-1.03, p=0.007) and higher level of negative symptoms (OR: 1.60, 95% CI: 1.07-2.39, p=0.021) were predictors of the relapse with moderate symptoms trajectory, while only longer duration of untreated psychosis (OR: 1.01, 95% CI: 1.00-1.02, p=0.030) predicted membership to the continuous severe symptoms trajectory. Two trajectories of negative symptoms were identified: symptom remission (51.0%) and continuous symptoms (49.0%). Predictors of the continuous symptoms trajectory were male sex (OR: 3.03, 95% CI: 1.48-6.02, p=0.002) and longer duration of untreated psychosis (OR: 1.01, 95% CI: 1.00-1.02, p=0.034). Trajectories displaying continuous positive and negative symptoms were linked to lower neurocognition, as measured by the Brief Assessment of Cognition in Schizophrenia (BACS) (z-score: -0.78, CI: -1.39 to -0.17, for continuous positive symptoms; z-score: -0.33, CI: -0.53 to -0.13, for continuous negative symptoms). The same trajectories were also linked to higher use of antipsychotic medication at 20-year follow-up (continuous positive symptoms: 78%; continuous negative symptoms: 67%). These findings suggest that the majority of patients with first-episode schizophrenia spectrum disorder have a trajectory with early stable remission of positive symptoms. Long duration of untreated psychosis and comorbid substance abuse are modifiable predictors of poor trajectories for positive symptoms in these patients. In about half of patients, negative symptoms do not improve over time. These symptoms, in addition to being associated with poor social and neurocognitive functioning, may prevent patients from seeking help.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.